Synairgen plc (LON:SNG)‘s stock had its “under review” rating reiterated by research analysts at N+1 Singer in a note issued to investors on Wednesday.

Separately, FinnCap restated a “corporate” rating on shares of Synairgen plc in a research report on Wednesday.

Shares of Synairgen plc (LON SNG) opened at 6.875 on Wednesday. The firm’s market capitalization is GBX 6.28 million. The stock has a 50 day moving average of GBX 7.84 and a 200-day moving average of GBX 15.26. Synairgen plc has a 1-year low of GBX 6.98 and a 1-year high of GBX 36.00.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at

Synairgen plc Company Profile

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease.

Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with's FREE daily email newsletter.